1082399-22-1

Basic information

• Product Name: 1-(4-(methylsulfonyl)benzyl)piperazine
• Synonyms: 1-(4-(methylsulfonyl)benzyl)piperazine
• CAS NO: 1082399-22-1
• Molecular Weight: 254.353
• Mol File: 1082399-22-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(4-(methylsulfonyl)benzyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-(methylsulfonyl)benzyl)piperazine(1082399-22-1)
• EPA Substance Registry System: 1-(4-(methylsulfonyl)benzyl)piperazine(1082399-22-1)

Safety Data

• Hazardous Substances Data: 1082399-22-1(Hazardous Substances Data)

Usage

Chemical class

Piperazine derivative It belongs to a class of chemical compounds that are derived from piperazine, a heterocyclic amine.

Structure

Substituted benzyl group The compound features a benzyl group (a phenylmethyl group) with a substitution at the 4-position.

Substituent

Methylsulfonyl group The benzyl group contains a methylsulfonyl (CH3SO2) group, which may contribute to the compound's pharmacological activity and bioavailability.

Potential applications

Central nervous system stimulant It has been studied for its potential use as a stimulant for the central nervous system.

Potential applications

Antidepressant The compound has also been investigated for its potential use as an antidepressant.

Potential applications

Treatment of neuropathic pain It has been explored for its potential use in treating neuropathic pain, a type of chronic pain caused by nerve damage.

Potential applications

Treatment of neurological disorders The compound has been considered for its potential use in treating other neurological disorders.

Importance

Promising candidate for medicinal chemistry The presence of the methylsulfonyl group in the benzyl moiety makes 1-(4-(methylsulfonyl)benzyl)piperazine a promising candidate for further research and development in the field of medicinal chemistry.

Upstream product

• 110-85-0 piperazine 
• 53606-06-7 4-(methylsulfonyl)benzyl bromide 
• 22821-77-8 p-methylsulfonylbenzyl alcohol 
• 40517-43-9 1-(chloromethyl)-4-(methylsulfonyl)benzene 

Downstream Products

• 1260629-44-4 C₃₀H₄₁ClN₄O₄S 

Relevant articles and documents

Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization

A series of chromones, bearing substituted amino groups or N-substituted carboxamide moieties in position 2, was synthesized and characterized in cellular assays for modulation of the ABC transporters ABCC1 (MDCKII-MRP1 cells), ABCB1 (Kb-V1 cells) and ABCG2 (MCF-7/Topo cells). The most potent ABCC1 modulators identified among these flavonoid-type compounds were comparable to the reference compound reversan regarding potency, but superior in terms of selectivity concerning ABCB1 and ABCG2 (2-[4-(Benzo[c][1,2,5]oxadiazol-5-ylmethyl)piperazin-1-yl]-5,7-dimethoxy-4H-chromen-4-one (51): ABCC1, IC50 11.3-1/4M; inactive at ABCB1 and ABCG2). Compound 51 was as effective as reversan in reverting ABCC1-mediated resistance to cytostatics in MDCKII-MRP1 cells and proved to be stable in mouse plasma and cell culture medium. Modulators, such as compound 51, are of potential value as pharmacological tools for the investigation of the (patho)physiological role of ABCC1.

CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS

This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and/or insulin sensitizers.